HORMONAL TREATMENTS FOR BREAST CANCER (ALL
drug has been approved by the FDA (Food and Drug
Administration) for the treatment of breast
mg (1 tablet) twice per day.
|Duration and timing:
Treatment for adjuvant therapy is continued to a
maximum of 5 years. In the treatment of stage IV
disease treatment is continued until disease
decrease in blood cells, especially white
cells (neutropenia) but also red cells
(anemia) and or platelets
possible nausea and vomiting (which may
be decreased or prevented with
menopausal symptoms (hot
flashes, night sweats, menstrual
irregularity), bone or tumor pain,
hypercalcemia (high calcium levels),
hyperlipidemia (high lipid levels).
vaginal bleeding, vaginal discharge, rare
instances of endometrial cancer
adverse effect on fertility is known;
this drug should not be taken by women
who are pregnant or breast feeding.
instances of pulmonary embolism have
occurred (blood clot going to the lung).
visual disturbances, cataracts, corneal
deposits, optic neuritis (swelling of the
optic nerve) and retinopathy
(disturbances in the function of the
elevated liver enzymes, hepatitis,
hepatic necrosis (liver death) and fatty
changes in the liver.
increased risk of developing blood clots.
In males decreased libido (sex drive) and
impotence has been reported.
1997 - TransMed Network